文献速递细菌感染、耐药与抗菌药物

一种新型KPC-113变异体赋予多重耐药铜绿假单胞菌对碳青霉烯类和头孢他啶-阿维巴坦耐药

A novel KPC-113 variant conferring carbapenem and ceftazidime-avibactam resistance in a multidrug-resistant Pseudomonas aeruginosa isolate.
PubMed 文献 · Clin Microbiol Infect · 2022-10-15

研究从临床铜绿假单胞菌分离株R20-14中鉴定出新型KPC-113变异体,该菌株同时耐碳青霉烯类和头孢他啶-阿维巴坦(CZA)。KPC-113在KPC-2的Ambler 266与267位之间插入甘氨酸,在转化子中同时介导对碳青霉烯类和CZA的耐药,且携带blaKPC-113的质粒具有高接合频率。KPC-113对碳青霉烯类和头孢他啶的催化能力降低,对阿维巴坦抑制反应差,结构建模提示其结合口袋较KPC-2更平坦。

要点

  • KPC-113在KPC-2的Ambler 266与267位间插入甘氨酸,介导碳青霉烯类和CZA耐药。
  • 携带blaKPC-113的质粒pR20-14与既往I型KPC编码铜绿假单胞菌质粒相似,接合频率高。
  • KPC-113对碳青霉烯类和头孢他啶催化能力降低,对阿维巴坦抑制反应差。

核心结论

  • KPC-113是一种同时介导CZA耐药和碳青霉烯类耐药的新型KPC变异体。
  • blaKPC-113可高效水平转移并同时灭活碳青霉烯类和CZA,需大力防止其在临床环境中传播。

研究设计与样本

  • 研究对临床铜绿假单胞菌分离株R20-14进行Illumina和Oxford Nanopore测序。
  • 通过接合实验评估质粒水平转移,用肉汤微量稀释法测定菌株最低抑菌浓度。
  • 检测不同碳青霉烯酶检测方法对KPC-113的可检出性,用分光光度计比较KPC-113与KPC-2的动力学参数。
  • 使用Schrödinger对KPC-2和KPC-113进行结构建模和分子对接。

主要发现

  • R20-14为序列型3903的多重耐药菌株,同时耐碳青霉烯类和CZA。
  • S1核酸酶脉冲场凝胶电泳和基因组分析显示携带blaKPC-113的质粒pR20-14,与既往报道的I型KPC编码铜绿假单胞菌质粒相似,接合频率高。
  • KPC-113在DH5α和PAO1转化子中同时赋予碳青霉烯类和CZA耐药。
  • 诊断试验显示KPC-113与KPC-2作用方式相似。
  • 与KPC-2相比,KPC-113对碳青霉烯类和头孢他啶的催化能力降低,对阿维巴坦抑制反应差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to characterize a novel KPC-113 variant from a clinical Pseudomonas aeruginosa isolate R20-14. METHODS: Genomic DNA of R20-14 was subjected to Illumina and Oxford Nanopore sequencing. The horizontal transmission of plasmid was evaluated with conjugation experiments. Minimum inhibitory concentrations of bacterial strains were obtained using broth microdilution methods. KPC-113 detectability of different carbapenemase detection methods was tested. The kinetic parameters of KPC-113 were compared with those of KPC-2 by a spectrophotometer. Structure modelling and molecular docking of KPC-2 and KPC-113 were performed using Schrödinger. RESULTS: R20-14, a sequence type 3903 multidrug-resistant strain, was resistant to carbapenems and ceftazidime-avibactam (CZA) concurrently. S1-nuclease pulsed-field gel electrophoresis and genomic analysis revealed a blaKPC-113-carrying plasmid pR20-14, which resembled the previously reported type I KPC-encoding P. aeruginosa plasmids and exhibited a high conjugation frequency. KPC-113, with a glycine residue insertion between Ambler positions 266 and 267 in KPC-2, conferred both carbapenem and CZA resistance in DH5α and PAO1 transformants. Diagnostic tests showed that KPC-113 acted in a similar manner to KPC-2. Compared with KPC-2, KPC-113 presented reduced catalytic ability to carbapenems and ceftazidime, meanwhile responding poorly to avibactam inhibition. Modelling structure revealed that KPC-113 possibly had a more flattened binding pocket than KPC-2, leading to the change of ligand binding modes. CONCLUSIONS: KPC-113 is a novel KPC variant mediating both CZA resistance and carbapenem resistance. It is of great concern that blaKPC-113 could transfer horizontally with great efficiency and inactivate carbapenems and CZA simultaneously. Great efforts should be made to prevent its spread in clinical settings.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Yang Q, Li Y, Fang L, et al. A novel KPC-113 variant conferring carbapenem and ceftazidime-avibactam resistance in a multidrug-resistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect. 2022. PMID: 36252790. doi:10.1016/j.cmi.2022.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。